Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells

Resistance to the breakpoint cluster region-abelson 1 (BCR-ABL1) tyrosine kinase inhibitor (TKI) imatinib poses a major problem when treating chronic myeloid leukemia (CML). Imatinib resistance often results from a secondary mutation in BCR-ABL1. However, in the absence of a mutation in BCR-ABL1, th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Tsubaki, Masanobu, Takeda, Tomoya, Kino, Toshiki, Sakai, Kazuko, Itoh, Tatsuki, Imano, Motohiro, Nakayama, Takashi, Nishio, Kazuto, Satou, Takao, Nishida, Shozo
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5503566/
https://ncbi.nlm.nih.gov/pubmed/28418880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16314
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares